The multilayered complexity of ceRNA crosstalk and competition

Nature, Journal Year: 2014, Volume and Issue: 505(7483), P. 344 - 352

Published: Jan. 1, 2014

Language: Английский

---

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

Cell, Journal Year: 2015, Volume and Issue: 163(2), P. 506 - 519

Published: Oct. 1, 2015

Language: Английский

---

PI3K and cancer: lessons, challenges and opportunities

Nature Reviews Drug Discovery, Journal Year: 2014, Volume and Issue: 13(2), P. 140 - 156

Published: Jan. 31, 2014

Language: Английский

---

Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation

Physiological Reviews, Journal Year: 2013, Volume and Issue: 93(3), P. 1019 - 1137

Published: July 1, 2013

Phosphoinositides (PIs) make up only a small fraction of cellular phospholipids, yet they control almost all aspects cell's life and death. These lipids gained tremendous research interest as plasma membrane signaling molecules when discovered in the 1970s 1980s. Research last 15 years has added wide range biological processes regulated by PIs, turning these into one most universal entities eukaryotic cells. PIs organelle biology regulating vesicular trafficking, but also modulate lipid distribution metabolism via their close relationship with transfer proteins. regulate ion channels, pumps, transporters both endocytic exocytic processes. The nuclear phosphoinositides have grown from being an epiphenomenon to area its own. As expected such pleiotropic regulators, derangements phosphoinositide are responsible for number human diseases ranging rare genetic disorders common ones cancer, obesity, diabetes. Moreover, it is increasingly evident that infectious agents hijack PI regulatory systems host cells intracellular movements, replication, assembly. result, converting enzymes began be noticed pharmaceutical companies potential therapeutic targets. This review attempt give overview this enormous field focusing on major developments diverse areas basic science linked physiology disease.

Language: Английский

---

Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Cancer Discovery, Journal Year: 2015, Volume and Issue: 6(2), P. 202 - 216

Published: Dec. 9, 2015

T cell-mediated immunotherapies are promising cancer treatments. However, most patients still fail to respond these therapies. The molecular determinants of immune resistance poorly understood. We show that loss PTEN in tumor cells preclinical models melanoma inhibits killing and decreases T-cell trafficking into tumors. In patients, correlates with decreased infiltration at sites, reduced likelihood successful expansion from resected tumors, inferior outcomes PD-1 inhibitor therapy. increased the expression immunosuppressive cytokines, resulting inhibited autophagy, which cell death. Treatment a selective PI3Kβ improved efficacy both anti-PD-1 anti-CTLA-4 antibodies murine models. Together, findings demonstrate promotes support rationale explore combinations PI3K-AKT pathway inhibitors.This study adds growing evidence oncogenic pathways tumors can promote antitumor response. As activation occur multiple types, results further evaluate combinatorial strategies targeting increase immunotherapy.

Language: Английский

---

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

Nature reviews. Cancer, Journal Year: 2014, Volume and Issue: 15(1), P. 7 - 24

Published: Dec. 23, 2014

Language: Английский

---

Nanomaterials for Theranostics: Recent Advances and Future Challenges

Chemical Reviews, Journal Year: 2014, Volume and Issue: 115(1), P. 327 - 394

Published: Nov. 25, 2014

ADVERTISEMENT RETURN TO ISSUEPREVReviewNEXTNanomaterials for Theranostics: Recent Advances and Future ChallengesEun-Kyung Lim†‡, Taekhoon Kim∥⊥, Soonmyung Paik#∇, Seungjoo Haam○, Yong-Min Huh*†, Kwangyeol Lee*∥View Author Information∥ Department of Chemistry, Korea University, Seoul 136-701, Korea† Radiology, Yonsei 120-752, Korea# Severance Biomedical Research Institute, University College Medicine, 120-749, Korea∇ Division Pathology, NSABP Foundation, Pittsburgh, Pennsylvania 15212, United States○ Chemical Biomolecular Engineering, Korea‡ BioNanotechnology Center, Institute Bioscience Biotechnology, Daejeon 305-806, Korea⊥ Electronic Materials Laboratory, Samsung Advanced Technology, Mt. 14-1, Nongseo-Ri, Giheung-Eup, Yongin-Si, Gyeonggi-Do 449-712, Korea*E-mail: [email protected]*E-mail: protected]Cite this: Chem. Rev. 2015, 115, 1, 327–394Publication Date (Web):November 25, 2014Publication History Received29 May 2012Published online25 November 2014Published inissue 14 January 2015https://pubs.acs.org/doi/10.1021/cr300213bhttps://doi.org/10.1021/cr300213breview-articleACS PublicationsCopyright © 2014 American SocietyRequest reuse permissionsArticle Views31405Altmetric-Citations1030LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum full text article downloads since 2008 (both PDF HTML) across all institutions individuals. These metrics regularly updated to reflect usage leading up last few days.Citations number other articles citing this article, calculated by Crossref daily. Find more information about citation counts.The Altmetric Attention Score is a quantitative measure attention that research has received online. Clicking on donut icon will load page at altmetric.com with additional details score social media presence given article. how calculated. Share Add toView InAdd Full Text ReferenceAdd Description ExportRISCitationCitation abstractCitation referencesMore Options onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Cancer,Cancer therapy,Cells,Metal oxide nanoparticles,Nanoparticles Get e-Alerts

Language: Английский

---

Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth

Nature, Journal Year: 2015, Volume and Issue: 527(7576), P. 100 - 104

Published: Oct. 16, 2015

Language: Английский

---

Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review

Cancer and Metastasis Reviews, Journal Year: 2013, Volume and Issue: 32(3-4), P. 623 - 642

Published: May 24, 2013

Language: Английский

---

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Aug. 18, 2023

Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, growth, and cycle progression. Growth factor signalling to transcription factors the PAM axis regulated by multiple cross-interactions with several other pathways, dysregulation of can predispose cancer development. most frequently activated human often implicated resistance anticancer therapies. Dysfunction components this such as hyperactivity PI3K, loss function PTEN, gain-of-function AKT, are notorious drivers treatment disease progression cancer. In review we highlight major dysregulations cancer, discuss results AKT mTOR inhibitors monotherapy co-administation antineoplastic agents clinical trials strategy for overcoming resistance. Finally, mechanisms targeted therapies, including immunology immunotherapies also discussed.

Language: Английский

---